Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Orthopedics Holds China-Australia Medial Pivot Knee Seminar

[2018-05-17] 

Shanghai, China – Recently, MicroPort® Orthopedics invited Dr. Warwich Bruce of Concord Clinical School of the University of Sydney for China-Australia Medical Pivot Knee Seminar held in Guangzhou, Guiyang, Wendeng, Shenyang, Shanghai and Hangzhou. Dr. Warwich Bruce introduced the design rational and application of the medial pivot knee to Chinese surgeons from the First Affiliated Hospital of Jinan University, Guizhou Province People's Hospital, the Wendeng Osteopath Hospital, Liaoning Province People's Hospital, Zhongshan Hospital of Fudan University and the Yuhang branch of the Second Affiliated Hospital of Zhejiang University School of Medicine.
 
As an Australian hip and knee orthopedic surgeon, Dr. Warwick Bruce worked on the study and application of medial pivot knee for two decades. He shared his understanding of the design concept and application of MicroPort® orthopedics medial pivot knee with Chinese orthopedic surgeons.
 
The seminar consists of two parts. In the first part, Dr. Warwick Bruce reviewed four bar link theory, a mainstream theory in the 70s, and history of the total knee implants. He pointed out that MicroPort®'s medial pivot is an innovative duplicate of natural knee based on the theory of human motion anatomy by citing a large number of theory studies and clinical data. In the second part, Dr. Warwick Bruce performed a surgery in Zhongshan Hospital of Fudan University to treat a patient with genu valgum and introduced the actual application of medial pivot knee in the total knee arthroplasty. The surgery was live broadcasted by Internet and attracted nearly 600 people to watch. The success of the surgery showed that medial pivot knee can not only be applied to gen varum patients but also genu valgum patients.
 
MicroPort® Orthopedics Medial Pivot Knee was launched in the US in 1998 with around 20 years' clinical history. Up to date, nearly 550,000 Medial Pivot Knees have been implanted globally. Several long-term studies have proved the advantages of medial pivot knee in total knee arthroplasty ("TKA"). The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities. The Journal of Arthroplasty has published a retrospective, comparative study that evaluated patient satisfaction after TKA using the MicroPort® Orthopedics' Evolution® Medial-Pivot Knee System and a posterior-stabilized ("PS") knee system. The study showed that patients who underwent the MP-TKA scored significantly better on the Forgotten Joint Score ("FJS") than those who underwent the PS-TKA, particularly with regard to deep knee flexion and stability of the prosthesis.
 
MicroPort® Orthopedics Medial Pivot Knee is gaining higher recognition among surgeons and patients due to its unique design. This workshop aims to provide a professional academic platform for overseas orthopedic experts. In the future, MicroPort® Orthopedics will invite more overseas experts to come to China for academic exchange, and jointly push the development of knee replacement, to provide more safe and effective medical solutions to improve patients' life quality.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® NeuroTech Attends 15th CFCVD
[Next]:MicroPort® Orthopedics Attends 2018 Qinling Joint Surgery Master Forum